StreetInsider.com News Articles

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Pauls brings more than 25 years of biopharmaceutical industry experience. Since 2020, he has served as chair of the board and chief executive officer of Savara Inc. (Nasdaq: SVRA), a clinical-stage company focused on rare respiratory diseases. From 2014 to 2019, he was president, CEO, and a board member of Strongbridge Biopharma (formerly Nasdaq: SBBP), which was later acquired by Xeris Pharmaceuticals. At Strongbridge, he led the company's Nasdaq initial public offering and oversaw commercialization of

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.

Palvella Therapeutics adds Matt Pauls to its board of directors

Tue, 30 Jun 2026 07:30:35 -0400

Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company, has appointed Matt Pauls, J.D., M.B.A., to its board of directors, according to a company press release.